Chronic Lung Disease in Medical Literature for More Than 200 Years Finally Has Its First Drug
Insmed’s Brinsupri is the first drug specifically approved for treating non-cystic fibrosis bronchiectasis, a progressive and potentially fatal lung disorder. The drug, licensed from AstraZeneca, inhibits activation of neutrophils, white blood cells that play a role in inflammatory and immune responses. The post Chronic Lung Disease in Medical Literature for More Than 200 Years Finally…
